+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Diurnal Variation in Prolactin, Adrenocorticotropin and Corticosterone Release Induced by Opiate Agonists in Intact and Adrenalectomized Rats

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Diurnal variations of the effectivity of β-endorphin (β-End), dynorphin (DYN), Met-enkephalin (Met-Enk), D-Met<sup>2</sup>-Pro<sup>5</sup>-enkephalinamide (D-Met-Pro-Enk) and morphine to induce prolactin (PRL) and adrenocorticotropin (ACTH)/corticosterone (CS) release in intact and adrenalectomized rats have been examined. The response to morphine (10 mg/kg s.c), Met-Enk (200 µg/rat i.c.v.) and D-Met-Pro-Enk (0.5 µg/rat i.c.v.) did not change with different times of the day, while that to β-End (0.5 µg/rat i.c.v.), DYN (1 µg/rat i.c.v.) and U50–488H, a selective kappa agonist (10 mg/kg s.c), showed a circadian rhythm in stimulating PRL release, with a higher increase in the afternoon (16.00–17.00 h) than in the morning (08.00–09.00 h). In adrenalectomized rats the loss of this circadian rhythm was shown. The CS release evoked by morphine, D-Met-Pro-Enk, Met-Enk and DYN was demonstrable only in the morning when the basal CS level was significantly lower than in the afternoon. The afternoon release of ACTH by morphine was higher than in the morning in adrenalectomized rats. β-End and U50–488H were equally active in the morning and in the afternoon in increasing CS secretion. The present results suggest that the diurnal rhythm in the response of CS and PRLrelease to opioids is in relation with the glucocorticoid secretion.

          Related collections

          Author and article information

          S. Karger AG
          02 April 2008
          : 46
          : 6
          : 475-480
          Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary
          124868 Neuroendocrinology 1987;46:475–480
          © 1987 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper


          Comment on this article